Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,290 from $1,171 and keeps an Overweight rating on the shares. The firm refreshed its model assumptions to incorporate recent developments in the GLP-1 space as well as insights from a proprietary primary care physician survey, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk Stock (NVO) Plunges After Alzheimer’s Drug Trial Misses Key Goal
- Eli Lilly price target raised to $1,300 from $1,100 at Bernstein
- The Week That Was, The Week Ahead: Macro & Markets, November 23, 2025
- Bristol Gate Capital Reduces Stake in Eli Lilly
- Gamco Investors Reduces Stake in Eli Lilly